Skip to content Skip to footer

Revolution starts here

The focus of cancer therapy is moving towards precision medicine. However, very few efficacious therapies are available for sarcomas. There is a clear unmet medical need as tumours frequently develop resistance to current therapies leading to treatment failure and disease progression. We are committed to delivering innovative therapeutic options for patients who have no specific therapies or have failed all currently available options.

Innovative drugs

Sartar uses principles of precision medicine, drug repurposing and reformulation to provide efficacious cancer therapies faster to the global markets.

Sartar Therapeutics is developing a new precision cancer treatment, SAR001, for soft tissue sarcomas, SAR001 specifically targets phosphodiesterase 3 -protein expressing tumours.

SAR001 is based on drug reformulation and repositioning of anagrelide, and has a long-acting profile that shows superior pharmacokinetic properties over oral administration, making it better tolerated and more convenient for use in therapy.

Rare life-threatening cancers

Soft-tissue sarcomas represent a rare and heterogenous group of mesenchymal tumors, accounting for 1 % of all adult cancers and more than 7 % of all pediatric cancers. Approximately 0.4 % of people will be diagnosed with a soft-tissue sarcoma during their lifetime.

Localized tumors can be treated with surgery and radiotherapy, but few, if any efficacious therapies are available for patients with metastatic tumors; the 5-year survival is 10 – 50 %.

Our operative team

CHIEF EXECUTIVE OFFICER

Katja Ivanitskiy, M.D.

Chief Executive Officer, Katja Ivanitskiy, M.D., Specialist in Public Health has joined the company as a CEO. She has vast experience of pharmaceutical medicine and pharmacovigilance, having worked in pharmaceutical industry and as a regulatory authority at the Finnish Medicines Agency. Prior to joining Sartar, Katja has been involved in Biodesign Finland entrepreneurial program, in startup product development as well as in building a new healthcare information system in Finland.

CHIEF OPERATIVE OFFICER

Mikael Maksimow, Ph.D.

Chief Operating Officer Mikael Maksimow has Master’s Degree in Biotechnology and Ph.D. in Immunology. Mikael has a long experience in early drug development from discovery stages to clinical trials, as well as experience in startup business development.

Board of Directors

CHAIRMAN OF THE BOARD

Harri Sihto, Ph.D.

The Chairman of the Board, Dr. Harri Sihto is a founding member of the Company. He is a biochemist, who received his Ph.D. degree in 2012 and was awarded with title of Adjunct Professor of Cancer Biology in 2015 at the University of Helsinki. Dr. Sihto’s research group investigates novel therapy targets in sarcomas and other rare cancers to discover new therapeutic options for the patients.

PROFESSOR

Olli Kallioniemi, M.D., Ph.D.

Professor Olli Kallioniemi is a founder and board member of Sartar Therapeutics. Professor Kallioniemi is an expert in a precision medicine. As a founding director of the Institute of Molecular Medicine Finland (FIMM), he had a crucial role in building a national research infrastructure required for precision medicine research. Now Prof. Kallioniemi is appointed as Director of SciLifeLab, a national center of molecular biosciences organized by Karolinska Institute, KTH Royal Institute of Technology, Stockholm University and Uppsala University in Sweden. Prof. Kallioniemi has 389 publications that are cited 40,000 times, as well as 20 patents. Prof. Kallioniemi brings invaluable insights on precision medicine strategies and development to the company.

SPECIALIST

Olli-Pekka Pulkka, Ph.D.

Olli-Pekka Pulkka, Ph.D. is a founder and board member of the Company. He is a cell and molecular biologist with a PhD from the University of Helsinki. His research is focused on the prognostic factors and novel therapeutic targets in GIST. Dr. Pulkka prepared his PhD thesis on the role of PDE3 as a therapy target in GIST.

INDUSTRY EXPERT

Pekka Simula, M.Sc.

Pekka Simula is a board member of Sartar Therapeutics. Mr. Simula has previously hold many life science and bioindustry expert positions such as Project Director at CRF Health, Global Program Manager at Varian Medical Systems,  CEO of Herantis Pharma and a founding CEO of Oncos Therapeutics, until the company’s merger with Norwegian Targovax in 2015. Mr. Simula is also a Director of the Finnish Biomedical Ecosystem FINBB and board member of several biotech companies.